2096.HK Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 май 2024 @ 06:58):

Stats
Объем за сегодня	1.12M
Средний объем	5.11M
Рыночная капитализация	14.75B
EPS	HKD0 ( 2024-03-28 )
Дата следующего отчета о доходах	( HKD0 ) 2024-06-14
Last Dividend	HKD0.176 ( 2023-06-19 )
Next Dividend	HKD0 ( N/A )
P/E	19.48
ATR14	HKD0.0100 (0.18%)

Объем Корреляция

Длинно: -0.04 (neutral)

Кратко: 0.27 (neutral)

Signal:(59.453) Neutral

Simcere Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Simcere Pharmaceutical Корреляция - Валюта/Сырье

0.31
( neutral )

0.60
( weak )

0.00
( neutral )

0.27
( neutral )

-0.78
( moderate negative )

Simcere Pharmaceutical Финансовые показатели

Annual	2023
Выручка:	HKD6.61B
Валовая прибыль:	HKD4.98B (75.43 %)
EPS:	HKD0.270

FY	2023
Выручка:	HKD6.61B
Валовая прибыль:	HKD4.98B (75.43 %)
EPS:	HKD0.270

FY	2023
Выручка:	HKD0
Валовая прибыль:	HKD0 (0.00 %)
EPS:	HKD0

FY	2022
Выручка:	HKD6.32B
Валовая прибыль:	HKD5.00B (79.08 %)
EPS:	HKD0.400

Financial Reports:

No articles found.

Simcere Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.176 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Simcere Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.58 - good (85.76%) | Divividend Growth Potential Score: 2.73 - Decrease likely (45.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.180	2021-06-29
Last Dividend	HKD0.176	2023-06-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD0.532	--
Avg. Dividend % Per Year	0.00%	--
Score	2.23	--
Div. Sustainability Score	8.58
Div.Growth Potential Score	2.73
Div. Directional Score	5.65	--

Next Divdend (Est)
(2025-03-31)

HKD0.176 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2628.HK	Ex Dividend Junior	2023-07-05	Annually	0.00%
1408.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
0489.HK	Ex Dividend Junior	2023-06-23	Annually	0.00%
6837.HK	No Dividend Player	2023-06-30	Annually	0.00%
1958.HK	Ex Dividend Junior	2023-06-28	Annually	0.00%
0991.HK	Ex Dividend Junior	2023-06-30	Sporadic	0.00%
0101.HK	Ex Dividend Junior	2023-09-12	Semi-Annually	0.00%
3328.HK	Ex Dividend Junior	2023-07-04	Annually	0.00%
1568.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
0596.HK	Ex Dividend Junior	2023-06-30	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.108	1.500	7.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0659	1.200	7.80	9.37	[0 - 0.3]
returnOnEquityTTM	0.0878	1.500	-0.135	-0.203	[0.1 - 1]
payoutRatioTTM	0.587	-1.000	4.13	-4.13	[0 - 1]
currentRatioTTM	2.10	0.800	4.50	3.60	[1 - 3]
quickRatioTTM	1.736	0.800	4.49	3.59	[0.8 - 2.5]
cashRatioTTM	0.747	1.500	6.96	10.00	[0.2 - 2]
debtRatioTTM	0.132	-1.500	7.81	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.0581	2.00	9.98	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.128	2.00	-0.0639	-0.128	[0 - 20]
debtEquityRatioTTM	0.198	-1.500	9.21	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.754	1.000	0.762	0.762	[0.2 - 0.8]
operatingProfitMarginTTM	0.108	1.000	9.85	9.85	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.106	1.000	-0.524	-0.524	[0.2 - 2]
assetTurnoverTTM	0.609	0.800	9.27	7.42	[0.5 - 2]
Total Score				8.58

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.79	1.000	8.30	0	[1 - 100]
returnOnEquityTTM	0.0878	2.50	-0.0869	-0.203	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.128	2.00	-0.0426	-0.128	[0 - 30]
dividendYielPercentageTTM	3.59	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0581	2.00	9.98	10.00	[0 - 30]
payoutRatioTTM	0.587	1.500	4.13	-4.13	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0229	1.000	-1.929	0	[0.1 - 0.5]
Total Score				2.73

Simcere Pharmaceutical

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.